Tesamorelin: The FDA-Approved Visceral Fat Peptide

Tesamorelin occupies a strange slot in the peptide world. It's the only GHRH analog ever FDA-approved (as Egrifta, for HIV-associated lipodystrophy), it has genuine Phase III trial data for visceral fat reduction, and yet the community treats it like an obscure option. That's mostly because it's expensive, the indication is narrow, and the visceral fat comes right back when you stop. But for a specific use case, nothing else in the GHRH family has this kind of data.

What it is, in one paragraph

Tesamorelin is the full 44-amino-acid human GHRH with a trans-3-hexenoic acid group stuck on the N-terminus to slow down aminopeptidase chew-through. It binds the same GHRH receptor as Sermorelin and CJC-1295, produces pulsatile endogenous GH release, and — uniquely — has real 26-week Phase III data showing 15–18% reduction in visceral adipose tissue. Not subcutaneous fat. Visceral.

Dosing: what people actually do

Tesamorelin dosing is the heaviest in the GHRH family, by a lot.

• Standard: 2 mg (2,000 mcg) sub-Q, once daily
• Site: Abdomen, rotate
• Timing: Before bed or AM fasted. Empty stomach matters — somatostatin kills the response
• Duration: 26 weeks is the trial length. Clinic use often runs longer
• Reconstitution: 10 mg vial + 5 mL BAC = 2 mg/mL → 1.0 mL per dose

A 10 mg vial is 5 days of dosing. That's the first thing people notice: this peptide burns through product.

"The mirror didn't lie. Four months in, waistband went down two inches. Stopped for a break, three months later I was right back where I started. Tes isn't a cycle, it's a faucet." — forum user

What it pairs with

Tesamorelin is usually run solo because the dose is already maximal for GHRH receptor activation. But a few common pairings show up:

Stack	Rationale
Tesamorelin alone	Maximal GHRH stimulation already; no need for a partner
Tesamorelin + Ipamorelin	GHRH + GHRP supra-additive — rare but used in aggressive body comp protocols
Tesamorelin + Semaglutide/Tirzepatide	"Belt and suspenders" visceral fat approach — big cost, contested logic

What it doesn't stack with: Sermorelin or CJC-1295 no DAC. Same receptor, no added benefit, just more money on the counter.

Red flags and side effects

The clinical trial record is actually pretty clean:

• Injection site reactions — redness, swelling, most common
• Flushing / warmth — classic GHRH response
• Mild water retention at the 2 mg dose
• Joint aches — reported, usually in the first month
• Glucose drift — watch fasting glucose / HbA1c if you're running it long

What people worry about and mostly don't see: severe water retention, CTS-style symptoms, insulin resistance at trial doses.

The honest limits

• Reaccumulation. The Phase III extension data is clear: stop Tesamorelin, VAT comes back over several months. This isn't a fat-loss peptide that re-sets your setpoint. It's a faucet. Close the tap and the tub refills
• Cost. Pharmaceutical Egrifta is absurdly expensive; research-grade Tesamorelin is still the most expensive GHRH analog by a lot
• Narrow label. The FDA approval is for HIV-associated lipodystrophy only. Off-label use for general visceral fat in non-HIV populations has much less controlled data
• The cognitive research is interesting but early. MGH's work on executive function improvements is compelling but small. Don't run Tesamorelin for brain health yet — the data isn't there

Where to go next

• For the full trial history, sequence detail, and mechanism, see the Pepperpedia Tesamorelin entry
• Body composition threads and real-world Tesamorelin results are in the Optimization forum
• Compare with the CJC-1295 field guide if you're trying to decide whether the Tesamorelin premium is worth it